Taiwan Biomaterial Co., Ltd. (6649) Stock Statistics & Valuation Metrics
Total Valuation
Taiwan Biomaterial Co., Ltd. has a market cap or net worth of TWD 1.45B. The enterprise value is TWD 1.62B.
- Market Cap
- TWD 1.45B
- Enterprise Value
- TWD 1.62B
Share Statistics
Taiwan Biomaterial Co., Ltd. has 42,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 42,000,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Taiwan Biomaterial Co., Ltd.’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 8.23%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 8.23%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 4.79M
- Profits Per Employee
- 1.28M
- Employee Count
- 46
- Asset Turnover
- 0.28
- Inventory Turnover
- 1.64
Valuation Ratios
The current PE Ratio of Taiwan Biomaterial Co., Ltd. is 45.87. Taiwan Biomaterial Co., Ltd.’s PEG ratio is 2.10.
- PE Ratio
- 45.87
- PS Ratio
- 8.27
- PB Ratio
- 3.47
- Price to FCF
- -36.94
- Price to Operating Cash Flow
- -65.83
- PEG Ratio
- 2.10
Income Statement
In the last 12 months, Taiwan Biomaterial Co., Ltd. had revenue of 220.40M and earned 58.93M in profits. Earnings per share was 1.40.
- Revenue
- 220.40M
- Gross Profit
- 123.10M
- Operating Income
- 60.83M
- Pretax Income
- 58.93M
- Net Income
- 58.93M
- EBITDA
- 76.30M
- Earnings Per Share (EPS)
- 1.40
Cash Flow
In the last 12 months, operating cash flow was -33.92M and capital expenditures -6.90M, giving a free cash flow of -40.82M billion.
- Operating Cash Flow
- -33.92M
- Free Cash Flow
- -40.82M
- Free Cash Flow per Share
- -0.66
Dividends & Yields
Taiwan Biomaterial Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 2.90%
- Dividend Per Share
- ―
- Dividend Yield
- 2.90%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.71%
- Earnings Yield
- 1.49%
Stock Price Statistics
- Beta
- 0.25
- 52-Week Price Change
- -38.94%
- 50-Day Moving Average
- 36.42
- 200-Day Moving Average
- 38.59
- Relative Strength Index (RSI)
- 29.99
- Average Volume (3m)
- 40.52K
Important Dates
Taiwan Biomaterial Co., Ltd. upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- May 08, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Taiwan Biomaterial Co., Ltd. as a current ratio of 8.53, with Debt / Equity ratio of 7.68%
- Current Ratio
- 8.53
- Quick Ratio
- 7.45
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -2.70
- Interest Coverage Ratio
- 82.09
Taxes
In the past 12 months, Taiwan Biomaterial Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Taiwan Biomaterial Co., Ltd. EV to EBITDA ratio is 36.21, with an EV/FCF ratio of -33.70.
- EV to Sales
- 7.54
- EV to EBITDA
- 36.21
- EV to Free Cash Flow
- -33.70
- EV to Operating Cash Flow
- -40.56
Balance Sheet
Taiwan Biomaterial Co., Ltd. has TWD 246.77M in cash and marketable securities with TWD 52.07M in debt, giving a net cash position of TWD 194.70M billion.
- Cash & Marketable Securities
- TWD 246.77M
- Total Debt
- TWD 52.07M
- Net Cash
- TWD 194.70M
- Net Cash Per Share
- TWD 4.64
- Tangible Book Value Per Share
- TWD 10.33
Margins
Gross margin is 51.43%, with operating margin of 10.12%, and net profit margin of 18.19%.
- Gross Margin
- 51.43%
- Operating Margin
- 10.12%
- Pretax Margin
- 18.19%
- Net Profit Margin
- 18.19%
- EBITDA Margin
- 20.83%
- EBIT Margin
- 11.92%
Analyst Forecast
The average price target for Taiwan Biomaterial Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 15.40%
- EPS Growth Forecast
- 22.48%
